Influence of UGT1A1 *6/*28 Polymorphisms on Irinotecan-Related Toxicity and Survival in Pediatric Patients with Relapsed/Refractory Solid Tumors Treated with the VIT Regimen

References

• Modak S, Kushner B, Basu E, Roberts S, Cheung N. Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: results of a Phase II study. Pediatr Blood Cancer. 2017;64(8):e26448. doi:10.1002/pbc.26448
   Web of Science ®Google Scholar
• Jinno H, Tanaka-Kagawa T, Hanioka N. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos. 2003;31(1):108–113. doi:10.1124/dmd.31.1.108
   PubMed Web of Science ®Google Scholar
• Bomgaars L, Bernstein M, Krailo M, et al. Phase II trial of irinotecan in children with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol. 2007;25(29):4622–4627. doi:10.1200/JCO.2007.11.6103
   PubMed Web of Science ®Google Scholar
• Campbell JM, Stephenson MD, Bateman E, Peters MD, Keefe DM, Bowen JM. Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Pharmacogenomics J. 2017;17(1):21–28. doi:10.1038/tpj.2016.58
   PubMed Web of Science ®Google Scholar
• Stewart C, Panetta J, O’Shaughnessy M, et al. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol. 2007;25(18):2594–2600. doi:10.1200/JCO.2006.10.2301
   PubMed Web of Science ®Google Scholar
• Nagar S, Blanchard R. Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan. Drug Metab Rev. 2006;38(3):393–409. doi:10.1080/03602530600739835
   PubMed Web of Science ®Google Scholar
• McGregor L, Spunt S, Furman W, et al. Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children’s oncology group study. Cancer. 2009;115(8):1765–1775. doi:10.1002/cncr.24175
   Web of Science ®Google Scholar
• Federico S, Pappo A, Sahr N, et al. A Phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies. Eur J Cancer. 2020;137:204–213. doi:10.1016/j.ejca.2020.06.014
   PubMed Web of Science ®Google Scholar
• Vassal G, Doz F, Frappaz D, et al. A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol. 2003;21(20):3844–3852. doi:10.1200/JCO.2003.08.175
   PubMed Web of Science ®Google Scholar
• Blaney S, Berg S, Pratt C, et al. A phase I study of irinotecan in pediatric patients: a pediatric oncology group study. Clin Cancer Res. 2001;7(1):32–37.
   PubMed Web of Science ®Google Scholar
• Mody R, Naranjo A, Van Ryn C, et al. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, Phase 2 trial. Lancet Oncol. 2017;18(7):946–957. doi:10.1016/S1470-2045(17)30355-8
   PubMed Web of Science ®Google Scholar
• Kweekel D, Guchelaar H, Gelderblom H. Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev. 2008;34(7):656–669. doi:10.1016/j.ctrv.2008.05.002
   PubMed Web of Science ®Google Scholar
• Nakayama G, Tanaka C, Uehara K, et al. The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer. Cancer Chemother Pharmacol. 2014;73(4):847–855. doi:10.1007/s00280-014-2416-x
   Web of Science ®Google Scholar
• Ahowesso C, Piccolo E, Li XM, et al. Relations between strain and gender dependencies of irinotecan toxicity and UGT1A1, CES2 and TOP1 expressions in mice. Toxicol Lett. 2010;192(3):395–401. doi:10.1016/j.toxlet.2009.11.017
   Web of Science ®Google Scholar
• Gupta E, Lestingi T, Mick R, Ramirez J, Vokes E, Ratain M. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 1994;54(14):3723–3725.
   PubMed Web of Science ®Google Scholar
• Cecchin E, Innocenti F, D’Andrea M, et al. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol. 2009;27(15):2457–2465. doi:10.1200/JCO.2008.19.0314
   PubMed Web of Science ®Google Scholar
• Zhu X, Ma R, Ma X, Yang G. Association of UGT1A1*6 polymorphism with irinotecan-based chemotherapy reaction in colorectal cancer patients: a systematic review and a meta-analysis. Biosci Rep. 2020;40. doi:10.1042/BSR20200576
   Web of Science ®Google Scholar
• Innocenti F, Undevia SD, Rosner GL, et al. Irinotecan (CPT-11) pharmacokinetics (PK) and neutropenia: interaction among UGT1A1 and transporter genes. J Clin Oncol. 2020.
   Google Scholar
• Wasserman E, Myara A, Lokiec F, et al. Severe CPT-11 toxicity in patients with Gilbert’s syndrome: two case reports. Ann Oncol. 1997;8(10):1049–1051. doi:10.1023/A:1008261821434
   Web of Science ®Google Scholar
• Xie F-W, Yh Y-H, Wang W, et al. Influence of UGT1A1 gene methylation level in colorectal cancer cells on the sensitivity of the chemotherapy drug CPT-11. Biomed Pharmacother. 2014;68(7):825–831. doi:10.1016/j.biopha.2014.08.012
   PubMed Web of Science ®Google Scholar
• Font A, Salazar R, Maurel J. Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms. Cancer Chemother Pharmacol. 2008;62(6):1075–1083. doi:10.1007/s00280-008-0700-3
   Web of Science ®Google Scholar
• Tobin PJ, Beale P, Noney L, et al. A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer. Cancer Chemother Pharmacol. 2006;57(3):309–316. doi:10.1007/s00280-005-0053-0
   PubMed Web of Science ®Google Scholar
• Buts J, Petit B, de Meyer R. Letter: loperamide in treatment of persistent diarrhoea in children. Br Med J. 1975;3(5986):766–767. doi:10.1136/bmj.3.5986.766-d
   Web of Science ®Google Scholar
• Han FF, Guo CL, Yu D, et al. Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients. Cancer Chemother Pharmacol. 2014.
   Web of Science ®Google Scholar
• Hikino K, Ozeki T, Koido M, et al. Comparison of effects of UGT1A1*6 and UGT1A1*28 on irinotecan-induced adverse reactions in the Japanese population: analysis of the Biobank Japan Project. J Hum Genet. 2019;64(12):1195–1202. doi:10.1038/s10038-019-0677-2
   Web of Science ®Google Scholar
• Ramchandani R, Wang Y, Booth B, et al. The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol. 2007;47(1):78–86.
   PubMed Web of Science ®Google Scholar
• Lankisch T, Schulz C, Zwingers T, et al. Gilbert’s Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk. Cancer Epidemiol, Biomarkers Prev. 2008;17(3):695–701.
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhou M, Hu M, et al. UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity: a meta-analysis. Asia Pac J Clin Oncol. 2018;14(5):e479–e489. doi:10.1111/ajco.13028
   PubMed Web of Science ®Google Scholar
• Zhang X, Yin J, Zhang J, Kong S, Zhang H, Chen X. UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis. Cancer Chemother Pharmacol. 2017;80(1):135–149. doi:10.1007/s00280-017-3344-3
   PubMed Web of Science ®Google Scholar
• Chen X, Liu L, Guo Z, et al. UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis. Cancer Chemother Pharmacol. 2017;79(6):1109–1117. doi:10.1007/s00280-017-3306-9
   PubMed Web of Science ®Google Scholar
• Liu X, Lu J, Duan W, et al. Predictive value of UGT1A1*28 polymorphism in irinotecan-based chemotherapy. J Cancer. 2017;8(4):691–703. doi:10.7150/jca.17210
   PubMed Web of Science ®Google Scholar
• Cheng L, Li M, Hu J, et al. UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians. Cancer Chemother Pharmacol. 2014;73(3):551–560. doi:10.1007/s00280-014-2382-3
   Web of Science ®Google Scholar
• Chen Y, Hu F, Li C, et al. The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis. Biomarkers. 2014;19(1):56–62. doi:10.3109/1354750X.2013.867534
   PubMed Web of Science ®Google Scholar
• Chen S, Hua L, Feng C, et al. Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang. BMC Gastroenterol. 2020;20(1):96. doi:10.1186/s12876-020-01227-w
   PubMed Web of Science ®Google Scholar
• Atasilp C, Chansriwong P, Sirachainan E, et al. Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy. Sci Rep. 2020;10(1):13486. doi:10.1038/s41598-020-70351-0
   PubMed Web of Science ®Google Scholar
• Ma X, Han S, Liu Y, Liu J, Fang J, Zhang Y. Pharmacogenetic impact of UGT1A1 polymorphisms on pulmonary neuroendocrine tumours treated with metronomic irinotecan-based chemotherapy in Chinese populations. J Pharm Pharmacol. 2020;72:1528–1535. doi:10.1111/jphp.13333
   Web of Science ®Google Scholar
• Zhu J, Liu A, Sun X, et al. UGT1A1Multicenter, randomized, Phase III trial of neoadjuvant chemoradiation with capecitabine and irinotecan guided by status in patients with locally advanced rectal cancer. J Clin Oncol. 2020;38:JCO2001932. doi:10.1200/JCO.20.01932
   Web of Science ®Google Scholar
• Dias M, Pignon J, Karapetis C, et al. The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis. Pharmacogenomics J. 2014;14(5):424–431. doi:10.1038/tpj.2014.16
   PubMed Web of Science ®Google Scholar
• Matsuoka H, Murakami R, Abiko K, et al. UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study. BMC Cancer. 2020;20(1):729. doi:10.1186/s12885-020-07225-1
   Web of Science ®Google Scholar
• Henriksen J, Bøttger P, Hermansen C, et al. Pazopanib-induced liver toxicity in patients with metastatic renal cell carcinoma: effect of UGT1A1 polymorphism on pazopanib dose reduction, safety, and patient outcomes. Clin Genitourin Cancer. 2020;18(1):62–68.e62. doi:10.1016/j.clgc.2019.09.013
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Iwasa S, Shoji H, et al. Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer. Gastric Cancer. 2019;22(4):778–784. doi:10.1007/s10120-018-00917-5
   PubMed Web of Science ®Google Scholar